Vascular Endothelial Growth Factor Levels in Ascites Between Chemonaive and Chemotreated Patients
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Vascular endothelial growth factor (VEGF) levels in malignant ascites have high diagnostic value for their discrimination from asictes of non-malignant origin. However, there have been no reports on the comparison of VEGF levels between malignant ascites of chemonaive and chemotreated patients. Materials and Methods: VEGF levels were measured in 44 ascites patients (cirrhosis ascites, 10; chemonaive patients, 21; chemotreated patients, 13) and compared to the level of carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA 19-9). The diagnostic parameters of sensitivity, specificity, and correlation among 3 markers were evaluated. Results: VEGF levels in malignant ascites of chemonaive and chemotreated patients were significantly higher than those in cirrhotic ascites (p<0.05). VEGF levels in ascites of chemonaive patients were significantly higher than those in chemotreated patients (p<0.05). A cutoff value of 10.4pg/mL was calculated using receiver operating characteristic curves (ROCs) for VEGF in chemotreated and chemonaive patients, which gave sensitivities of 75.0% and 53.8% and specificities of 69.6% and 47.1%, respectively. Positive correlations were observed between VEGF and CEA (r=0.353, p<0.05) as well as between VEGF and CA19-9 (r=0.367, p<0.05) in ascites. Conclusion: VEGF levels could be a useful tumor marker for malignant ascites, but its value should carefully be interpreted because of lesser reliability in chemotreated ones.
Abstract
Purpose: Vascular endothelial growth factor (VEGF) levels in malignant ascites have high diagnostic value for their discrimination from asictes of non-malignant origin. However, there have been no reports on the comparison of VEGF levels between malignant ascites of chemonaive and chemotreated patients. Materials and Methods: VEGF levels were measured in 44 ascites patients (cirrhosis ascites, 10; chemonaive patients, 21; chemotreated patients, 13) and compared to the level of carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA 19-9). The diagnostic parameters of sensitivity, specificity, and correlation among 3 markers were evaluated. Results: VEGF levels in malignant ascites of chemonaive and chemotreated patients were significantly higher than those in cirrhotic ascites (p<0.05). VEGF levels in ascites of chemonaive patients were significantly higher than those in chemotreated patients (p<0.05). A cutoff value of 10.4pg/mL was calculated using receiver operating characteristic curves (ROCs) for VEGF in chemotreated and chemonaive patients, which gave sensitivities of 75.0% and 53.8% and specificities of 69.6% and 47.1%, respectively. Positive correlations were observed between VEGF and CEA (r=0.353, p<0.05) as well as between VEGF and CA19-9 (r=0.367, p<0.05) in ascites. Conclusion: VEGF levels could be a useful tumor marker for malignant ascites, but its value should carefully be interpreted because of lesser reliability in chemotreated ones.
참고문헌 (30)
- Aslam N, "Malignant ascites: new concepts in pathophysiology, diagnosis, and management", Arch Intern Med, 161, pp.2733~2737 (2001)
- Colli A, "Diagnostic accuracy of fibronectin in the differential diagnosis of ascites", Cancer, 58, pp.2489~2493 (1986)
- Sevinc A, "The utility of lactate dehydrogenase isoenzyme pattern in the diagnostic evaluation of malignant and nonmalignant ascites", J Natl Med Assoc, 97, pp.79~84 (2005)
- Yildirim B, "Patients with spontaneous bacterial peritonitis, and mlignant and cirrhotic ascites", J Natl Med Assoc, 97, pp.276~280 (2005)
- Siddiqui RA, "Evaluation of fibronectin as a marker of malignant ascites", J Gastroenterol Hepatol, 7, pp.161~164 (1992)
- Rana SV, "Usefulness of ascitic fluid cholesterol as a marker for malignant ascites", Med Sci Monit, 11, pp.136~142 (2005)
- Zebrowski BK, "Markedly elevated levels of vascular endothelial growth factor in malignant ascites", Ann Surg Oncol, 6, pp.373~378 (1999)
- Dong WG, "Role of VEGF and CD44v6 in differentiating benign from malignant ascites", World J Gastroenterol, 9, pp.2596~2600 (2003)
- Abramov Y, "Markedly elevated levels of vascular endothelial growth factor, fibroblast growth factor, and interleukin 6 in Meigs syndrome", Am J Obstet Gynecol, 184, pp.354~355 (2001)
- Sun XM, "Clinical significance of detecting VEGF, CD44v6, MMP-2 and MMP-9 in malignant ascites", Ai Zheng, 23, pp.85~89 (2004)
- Nascimento I, "Carvalho S, et al. Vascular endothelial growth factor (VEGF) levels as a tool to discriminate between malignant and nonmalignant ascites", APMIS, 112, pp.585~587 (2004)
- Kraft A, "Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease", Cancer, 85, pp.178~187 (1999)
- Kuwahara K, "Gemcitabine suppresses malignant ascites of human pancreatic cancer: correlation with VEGF expression in ascites", Oncol Rep, 11, pp.73~80 (2004)
- Manenti L, "Circulating plasma vascular endothelial growth factor in mice bearing human ovarian carcinoma xenograft correlates with tumor progression and response to therapy", Mol Cancer Ther, 4, pp.715~725 (2005)
- Keyes K, "An in vitro tumor model: analysis of angiogenic factor expression after chemotherapy", Cancer Res, 62, pp.5597~5602 (2002)
- Lissoni P, "Chemotherapy and angiogenesis in advanced cancer: vascular endothelial growth factor (VEGF) decline as predictor of disease control during taxol therapy in metastatic breast cancer", Int J Biol Markers, 15, pp.308~311 (2000)
- Fernandes LC, "Value of carcinoembryonic antigen and cytokeratins for the detection of recurrent disease following curative resection of colorectal cancer", World J Gastroenterol, 12, pp.3891~3894 (2006)
- Lowe D, "Patient with markedly elevated CA 19-9 not associated with malignancy", South Med J, 99, pp.306~308 (2006)
- Nowak J, "Carbohydrate antigens CA 19-9, CA 242, CA 50 in liver diseases", Wiad Lek, 51, pp.484~491 (1998)
- Trapé J, "Clinical evaluation of the simultaneous determination of tumor markers in fluid and serum and their ratio in the differential diagnosis of serous effusions", Tumour Biol, 25, pp.276~281 (2004)
- Chen SJ, "Clinical value of tumour markers and serum- ascites albumin gradient in the diagnosis of malignancy- related ascites", J Gastroenterol Hepatol, 9, pp.396~400 (1994)
- Cascinu S, "Tumor markers in the diagnosis of malignant serous effusions", Am J Clin Oncol, 20, pp.247~250 (1997)
- Miles LE, "Labelled antibodies and immunological assay systems", Nature, 219, pp.186~189 (1968)
- Denstman F, "Comparing predictive decision rules in postoperative CEA monitoring", Cancer, 58, pp.2089~2095 (1986)
- Del Villano BC, "Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19-9", Clin Chem, 29, pp.549~552 (1983)
- Light RW, "Pleural effusions: the diagnostic separation of transudates and exudates", Ann Intern Med, 77, pp.507~513 (1972)
- WHO Handbook for Reporting Results of Cancer Treatment, "WHO Offset Publication No. 48. Genev" (1979), World Health Organization
- Miller AB, "Reporting results of cancer treatment", Cancer, 47, pp.207~214 (1981)
- Hyodo I, "Clinical significance of plasma vascular endothelial growth factor in gastrointestinal cancer", Eur J Cancer, 34, pp.2041~2045 (1998)
- Loewenstein MS, "Carcinoembryonic antigen assay of ascites and detection of malignancy", Ann Intern Med, 88, pp.635~638 (1978)